
Loading, please wait...

Loading, please wait...

Recent epidemiological data reveal a concerning link between maternal substance exposure and congenital heart disease. Consequently, researchers have identified that cannabinoid use pregnancy ASD (atrial septal defect) rates are significantly influenced by ethnic factors. This study, published in the Journal of Perinatology, suggests that the interaction between cannabinoids and genetic background plays a critical role in fetal development. Therefore, understanding these variables is essential for modern neonatal care.
The study utilized state-based data from the US National Birth Defects Prevention Network to explore how substance use and ethnicity intersect. Notably, the findings showed that African American and American Indian populations face a much higher relative risk of ASD. Specifically, the relative risks were 2.40 and 2.31, respectively. Moreover, additive models confirmed that the interaction between ethnicity and cannabis was statistically significant. This evidence implies that certain populations may be genetically more vulnerable to the teratogenic effects of cannabinoids.
Researchers applied robust statistical estimations to confirm the causal relationships between these factors. In addition, the study highlighted that Nevada exhibited an exponential doubling time of ASD rates amongst Asians and Pacific Islanders. Because cannabinoids like THC and CBD can cross the placenta, they likely interfere with early cardiogenesis. Furthermore, the rising legalization of cannabis products has correlated with a supra-exponential increase in ASD prevalence. Thus, clinical awareness regarding substance use during the first trimester is more critical than ever before.
Healthcare providers should prioritize detailed prenatal screening for substance exposure. Because the study meets epidemiological causal criteria, clinicians must counsel patients on the potential cardiac risks of cannabis. Additionally, targeted awareness campaigns might help mitigate these risks in high-risk ethnic groups. Although the study focuses on the USA, the biological implications regarding cannabinoid genotoxicity remain relevant globally. Consequently, improving patient education on fetal outcomes is a necessary step for preventing congenital malformations.
Cannabinoids can cross the placental barrier and potentially interfere with the signaling pathways required for proper cardiac septation, leading to defects like ASD.
Current research indicates that both THC and CBD are significantly associated with increased atrial septal defect rates, particularly when interacting with specific ethnic genetic backgrounds.
Ethnic modulation suggests that genetic predispositions may make certain populations more susceptible to the teratogenic or genotoxic effects of cannabinoids during embryonic development.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Reece AS et al. Cannabinoid impacts on ethnic modulation of atrial septal defect prevalence USA. J Perinatol. 2026 May 27. doi: 10.1038/s41372-026-02717-7. PMID: 42204358.
Reece AS, Hulse GK. Impact of Cannabis and Cannabis Legalization on US Atrial Septal Defect Rates. J Xenobiot. 2026 Mar 1;16(2):43. doi: 10.3390/jox16020043.
Lo J, et al. Cannabis Use in Pregnancy and Neonatal Outcomes: A Systematic Review and Meta-Analysis. JAMA Pediatr. 2025 May 5. doi: 10.1001/jamapediatrics.2025.0123.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A US study finds that cannabinoid exposure and ethnic factors significantly drive the prevalence of atrial septal defects (ASD) in neonates....
4 months ago

Explore vital recurrent stroke predictors in lacunar stroke patients managed with intensive blood pressure lowering. This analysis examines trial findings from SPS3 to uncover residual vascular risks, metabolic factors, and targeted secondary prevention strategies for high-risk neurological patients.
Today

Odisha has established India's first state-level clinical protocol specifically tailored for pregnant women with sickle cell disease. Developed with NHM and UNICEF, the framework provides structured antenatal screening, crisis mitigation, standardized referral pathways, and specialized interdisciplinary care.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

Mitochondria-targeted nanoparticles self-assembled from EGCG and L-glutamic acid effectively restore mitochondrial homeostasis, suppress synovial inflammation, and attenuate chondrocyte senescence in osteoarthritis, offering a promising disease-modifying nanotherapy.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today